Addressing the Challenges of Commercial-Scale Viral Vector Production
Interview with Dr. Nicole Faust, CEO & CSO, CEVEC
Bioinsights – March 15, 2018
Over the past few years there has been a significant increase in gene therapy research leading to a growing number of therapies in clinical development which address common diseases including Alzheimer’s, Parkinson’s or rheumatoid arthritis. As a consequence bottlenecks in manufacturing arise during late stage clinical trials and particularly when entering the market.
CEVEC has developed a novel production system, based on its proprietary CAP-GT suspension cell technology, that allows for easier to handle, scalable and highly efficient viral vector production to close the production gap in gene therapy applications.